Dr. Marty on Letermovir for CMV Prevention After Stem Cell Transplant – OncLive
OncLive |
Dr. Marty on Letermovir for CMV Prevention After Stem Cell Transplant
OncLive CMV is the most common infection that occurs after stem cell transplants. In the United State, the prevalence of CMV infection is approximately 50% to 60%. Because of drugs given during transplants, the virus has the opportunity to come out of latency. Merck's Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in Bone … |
